Lisata Therapeutics (NASDAQ:LSTA – Get Free Report) and Mangoceuticals (NASDAQ:MGRX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.
Earnings and Valuation
This table compares Lisata Therapeutics and Mangoceuticals’ revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lisata Therapeutics | N/A | N/A | -$54.22 million | ($9.91) | -0.26 |
| Mangoceuticals | $10,000.00 | 1,939.52 | -$2.00 million | N/A | N/A |
Mangoceuticals has higher revenue and earnings than Lisata Therapeutics.
Institutional & Insider Ownership
Analyst Recommendations
This is a summary of current recommendations for Lisata Therapeutics and Mangoceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lisata Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| Mangoceuticals | 0 | 0 | 0 | 0 | N/A |
Lisata Therapeutics currently has a consensus price target of $15.00, indicating a potential upside of 474.71%. Given Lisata Therapeutics’ higher possible upside, research analysts clearly believe Lisata Therapeutics is more favorable than Mangoceuticals.
Profitability
This table compares Lisata Therapeutics and Mangoceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lisata Therapeutics | N/A | -36.22% | -33.15% |
| Mangoceuticals | N/A | N/A | N/A |
About Lisata Therapeutics
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 1b/2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; HONEDRA, a recipient of SAKIGAKE designation critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and LSTA201, a CD34+ cell therapy for the treatment of chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
About Mangoceuticals
Mangoceuticals, Inc. focuses on develops, markets, and sells various men's wellness products and services through a telemedicine platform. It offers erectile dysfunction products under the Mango brand name. The company sells its products through online website mangorx.com. Mangoceuticals, Inc. was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.
Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
